Gene expression profile is associated with chemoradiation resistance in rectal cancer

Colorectal Disease

Volumn 16, Issue 1, 2014, Pages 57-66

  Gantt, G A ^a   Chen, Y ^b   Dejulius, K ^a   Mace, A G ^a   Barnholtz Sloan, J ^b   Kalady, M F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Gene Expression Profile; Microarray; Neoadjuvant Chemoradiation; Rectal Cancer; Response to Therapy

Indexed keywords

DOUBLE STRANDED DNA; MESSENGER RNA; NUCLEOTIDE;

ADULT; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CANONICAL ANALYSIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE STRANDED DNA BREAK; FEMALE; GENE EXPRESSION; HOMOLOGOUS RECOMBINATION; HUMAN; INSTITUTIONAL REVIEW; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM CANCER; RECTUM CARCINOMA; RECTUM RESECTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

GENE EXPRESSION PROFILE; MICROARRAY; NEOADJUVANT CHEMORADIATION; RECTAL CANCER; RESPONSE TO THERAPY;

ADENOCARCINOMA; ADULT; AGED; CHEMORADIOTHERAPY; DNA REPAIR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RADIATION TOLERANCE; RECTAL NEOPLASMS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84890280249     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12395     Document Type: Article

References (47)

1. Silberfein EJ, Kattepogu KM, Hu CY et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol 2010; 17: 2863-9.
2. Janjan NA, Khoo VS, Abbruzzese J et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44: 1027-38.
3. de Campos-Lobato LF, Stocchi L, da Luz Moreira A et al. Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers. Ann Surg Oncol 2010; 17: 1758-66.
4. Stipa F, Chessin DB, Shia J et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol 2006; 13: 1047-53.
5. Rodel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-96.
6. Park IJ, You YN, Agarwal A et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012; 30: 1770-6.
7. Theodoropoulos G, Wise WE, Padmanabhan A et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002; 45: 895-903.
8. Kuo LJ, Liu MC, Jian JJ et al. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 2007; 14: 2766-72.
9. de Campos-Lobato LF, Stocchi L, da Luz Moreira A et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol 2011; 18: 1590-8.
10. Zorcolo L, Rosman AS, Restivo A et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol 2012; 19: 2822-32.
11. Habr-Gama A, Perez RO, Proscurshim I et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006; 10: 1319-28; discussion 1328-9.
12. Maas M, Nelemans PJ, Valentini V et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-44.
13. Garcia-Aguilar J, Shi Q, Thomas CR Jr et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 2012; 19: 384-91.
14. Kalady MF, Dejulius K, Church JM, Lavery IC, Fazio VW, Ishwaran H. Gene signature is associated with early stage rectal cancer recurrence. J Am Coll Surg 2010; 211: 187-95.
15. Kalady MF, Coffey JC, Dejulius K, Jarrar A, Church JM. High-throughput arrays identify distinct genetic profiles associated with lymph node involvement in rectal cancer. Dis Colon Rectum 2012; 55: 628-39.
16. Saigusa S, Inoue Y, Tanaka K et al. Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy. J Cancer Res Clin Oncol 2013; 139: 131-8.
17. Grade M, Wolff HA, Gaedcke J, Ghadimi BM. The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch Surg 2012; 397: 543-55.
18. NCCN. NCCN Clinical Practice Guidelines in Oncology -Rectal Cancer V.4.2013. 2012; Available at: http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf (accessed November 2013).
19. Washington MK, Berlin J, Branton P et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 2009; 133: 1539-51.
20. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012; 12: 801-17.
21. Stracker TH, Petrini JH. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol 2011; 12: 90-103.
22. Soderlund K, Stal O, Skoog L, Rutqvist LE, Nordenskjold B, Askmalm MS. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys 2007; 68: 50-8.
23. Choudhury A, Nelson LD, Teo MT et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010; 70: 7017-26.
24. Araki K, Yamashita T, Reddy N et al. Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer. Br J Cancer 2010; 103: 1822-30.
25. Huang Y, Zhang X, Jiang W et al. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique. Eur J Obstet Gynecol Reprod Biol 2012; 165: 96-103.
26. Vermaat JS, van der Tweel I, Mehra N et al. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 2010; 21: 1472-81.
27. Staub E, Groene J, Heinze M et al. An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med (Berl) 2009; 87: 633-44.
28. Chen YT, Chen CL, Chen HW et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J Proteome Res 2010; 9: 5803-15.
29. Reddavide R, Misciagna G, Caruso MG et al. Tissue expression of glycated apolipoprotein B in colorectal adenoma and cancer. Anticancer Res 2011; 31: 555-9.
30. Hyung SW, Lee MY, Yu JH et al. A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers. Mol Cell Proteomics 2011; 10: M111.011023. doi: 10.1074/mcp.M111.011023
31. Lin CK, Chao TK, Lai HC, Lee HS. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. Am J Clin Pathol 2012; 137: 971-7.
32. Tsai WC, Lin CK, Yang YS et al. The correlations of LMX1A and osteopontin expression to the clinicopathologic stages in pancreatic adenocarcinoma. Appl Immunohistochem Mol Morphol 2012; 21: 395-400.
33. Chao TK, Yo YT, Liao YP et al. LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer. Gynecol Oncol 2012; 128: 475-82.
34. Mallikarjuna K, Sundaram CS, Sharma Y et al. Comparative proteomic analysis of differentially expressed proteins in primary retinoblastoma tumors. Proteomics Clin Appl 2010; 4: 449-63.
35. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5: 4589-96.
36. Farias-Eisner G, Su F, Robbins T, Kotlerman J, Reddy S, Farias-Eisner R. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet Gynecol 2010; 202: 73.
37. Brettingham-Moore KH, Duong CP, Greenawalt DM et al. Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clin Cancer Res 2011; 17: 3039-47.
38. Ghadimi BM, Grade M, Difilippantonio MJ et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005; 23: 1826-38.
39. Kim IJ, Lim SB, Kang HC et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 2007; 50: 1342-53.
40. Watanabe T, Komuro Y, Kiyomatsu T et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 2006; 66: 3370-4.
41. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev 2009; 35: 201-9.
42. Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 2010; 7: 340-7.
43. Rimkus C, Friederichs J, Boulesteix AL et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 2008; 6: 53-61.
44. Akiyoshi T, Kobunai T, Watanabe T. Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today 2012; 42: 713-9.
45. Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. J Oncol Pharm Pract 2013. doi: 10.1177/1078155212474047 [e-pub ahead of print].
46. Kelley RK, Venook AP. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer 2011; 10: 73-80.
47. Nishioka M, Shimada M, Kurita N et al. Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. Cancer Genomics Proteomics 2011; 8: 87-92.